Physician profile
Emily D Roman
NPI 1700280146
$12,911.49
in general payments reported to CMS, 2019-2025
43 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,156 · 2022: $2,350 · 2023: $2,114 · 2024: $2,942 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,365 · Education: $41.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,364.50 |
| Education | $41.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,256.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,254.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,239.32 | 2021-2025 | Breztri, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $956.01 | 2021-2025 | Jardiance, Ofev |
| Amgen INC. | $806.84 | 2021-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $721.97 | 2021-2025 | |
| Novo Nordisk INC | $613.98 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $604.67 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $548.24 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $473.56 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $349.08 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $320.41 | 2021-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $315.89 | 2021-2024 | Trintellix, Glassia |
| Lundbeck LLC | $302.83 | 2023-2025 | Rexulti |
| Eisai INC. | $244.86 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $230.95 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $159.40 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $156.85 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $152.05 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $144.75 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $131.14 | 2021-2024 | Eliquis |
| Ironwood Pharmaceuticals, INC | $123.24 | 2021-2024 | Linzess |
| Baxter Healthcare | $112.25 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Amneal Pharmaceuticals LLC | $82.47 | 2021-2022 | |
| Abbott Laboratories | $71.71 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $69.63 | 2023 | |
| Nestle Healthcare Nutrition INC. | $43.90 | 2021 | |
| Intra-Sana Laboratories | $40.96 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Novartis Pharmaceuticals Corporation | $39.68 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.97 | 2022-2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $33.40 | 2024 | Uptravi, Opsumit |
| Sanofi Pasteur INC. | $31.49 | 2021-2022 | |
| Vistapharm, INC. | $29.17 | 2021 | |
| Almatica Pharma LLC | $28.65 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $24.73 | 2025 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $22.61 | 2022 | |
| Clarus Therapeutics INC. | $21.71 | 2021 | |
| Shield Therapeutics INC | $21.42 | 2025 | |
| Allergan, INC. | $20.67 | 2021 | |
| Daiichi Sankyo INC. | $20.25 | 2024 | Injectafer |
| Medtronic, INC. | $19.39 | 2021 | |
| Linus Health, INC. | $17.82 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.